Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This study will look at the treatment effect of DiaPep277 on preservation of beta-cell
function, as defined by meal-stimulated secretion of insulin. DiaPep277 is a peptide that
changes the way the immune system behaves, stopping its attack on the beta-cells.
Adults (>20 years) with newly diagnosed (<6 months) type 1 diabetes will be treated with 10
injections of DiaPep277 or Placebo over a 2-year treatment and follow-up period.